Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

Cannabis: Difference between revisions

From Pharmacopedia
[checked revision][checked revision]
Rebuild Cannabis page as PlantMedTemplate exemplar. Full content across all template sections: botany, Central Asian origin + Scythian/Chinese/Hindu/Islamic/19th-century-Western traditional uses, full preparations spectrum (flower/hash/kief/tincture/edible/concentrate/full-spectrum/isolate), constituents (cannabinoids + terpenes with entourage-effect framing), PK (CYP2C9 + CYP3A4 metabolism with lipophilic distribution + biphasic elimination), PD (CB1/CB2 receptors + endocannabinoid system +...
Rebuild Cannabis as canonical plant-medicine page per project_plant_medicine_page_spec.md (set 2026-05-18 by web-claude editorial directive). History-first spine (Turpan burial lede; Shennong, Atharvaveda, Scythian/Pamir, Avicenna, O'Shaughnessy, USP 1850-1942, IHDC 1894, 1937 Tax Act, prohibition arc, modern reform from CA 1996 through Epidiolex 2018). Six Pendell quotes spread through 6 sections (A botany, B constituents, C history-prohibition, E safety w/ Francis Young DEA-ALJ 1988 source,...
Line 1: Line 1:
{{PlantMedTemplate
{{PlantMedTemplate
| images               =
| images           = [[File:Cannabis_sativa_plant.JPG|frameless|260px|alt=A mature Cannabis sativa plant in the field, photographed by Chmee2, 2010, CC BY-SA 3.0]]<br><small>''Cannabis sativa'' &middot; photo: Chmee2, [https://creativecommons.org/licenses/by-sa/3.0/ CC BY-SA 3.0]</small>
| binomial            = Cannabis sativa L.
| binomial        = Cannabis sativa
| family              = Cannabaceae
| family          = Cannabaceae
| common_names        = cannabis, marijuana, marihuana, hemp, ganja, weed, pot, dagga, kif, dope, herb, flower
| common_names    = hemp, marijuana, bhang, ganja, hashish, weed
| native_range        = Central Asia (debated; Eurasian steppe between modern Mongolia and the Caucasus is the leading candidate)
| native_range    = Central Asia
| cultivars            = ''C. sativa'', ''C. indica'', and ''C. ruderalis'' under the older tripartite taxonomy; the modern '''chemovar''' classification (type I THC-dominant, type II mixed, type III CBD-dominant, type IV CBG-dominant, type V essentially cannabinoid-free) is increasingly preferred by chemists
| parts_used      = flowering tops, leaves, seeds, fiber
| parts_used          = primarily the flowering tops of unpollinated female plants; secondarily leaves, resin glands (trichomes), and seeds
| interactionsummary =
| cultivation          = global; both outdoor (warm temperate to subtropical) and indoor under artificial light; selective breeding has driven THC content in modern flower from roughly 3 to 4% in the 1970s to 15 to 25% today
| pharmacokinetics =
| preparations_summary = flower, hash, kief, tincture, edible, vaporized concentrate, full-spectrum extract, isolate
| pharmacodynamics =
| constituents_summary = >120 cannabinoids and >200 terpenes; principal cannabinoids include [[THC|Δ9-THC]], [[CBD|CBD]], [[CBN|CBN]], [[CBG|CBG]], [[THCV]], CBC; principal terpenes include myrcene, limonene, α-pinene, linalool, β-caryophyllene
| intro           = Some time in the fourth century BC, a young woman was buried near what is now Turpan, in far western China, and laid out beneath a shroud of thirteen whole cannabis plants, their roots gathered at her pelvis and their tops fanned across her chest.<ref name="jiang2016">Jiang H, Wang L, Merlin MD, et al. Ancient Cannabis Burial Shroud in a Central Eurasian Cemetery. ''Economic Botany''. 2016 Sep;70(3):213-221. DOI: 10.1007/s12231-016-9351-1.</ref> She was one of countless people, across at least three thousand years, for whom this plant was worth carrying into the grave. The history of cannabis is older than almost any other medicine, and it is bound up from the beginning with ritual, with healing, with intoxication, and, in its most recent and strangest chapter, with prohibition.
| mechanism            = phytocannabinoids act primarily at the CB1 and CB2 cannabinoid receptors of the endocannabinoid system; numerous secondary actions at TRP channels, GPR55, PPARs, serotonin 5-HT1A, and others, with constituent-specific profiles
| traditional_uses = Cannabis may be among the first plants that human beings ever cultivated. It grew readily on the disturbed ground around early settlements, and it offered three distinct gifts at once: a strong fiber, an oil-rich and edible seed, and a resin that altered the mind. Which of these was wanted first cannot now be known.
| pregnancy            = Avoid; THC crosses the placenta and enters breast milk; chronic prenatal exposure associated with low birth weight and neurodevelopmental effects.
| legal                = US Schedule I federally; legal for medical or recreational use under varying frameworks in most US states and many countries as of 2026
| interactionsummary  = [[THC]] cleared principally by [[Enzyme:CYP2C9|CYP2C9]] and [[Enzyme:CYP3A4|CYP3A4]]; [[CBD]] is a clinically meaningful inhibitor of [[Enzyme:CYP2C19|CYP2C19]], [[Enzyme:CYP3A4|CYP3A4]], [[Enzyme:CYP2C9|CYP2C9]], and several UGTs, and raises plasma concentrations of clobazam, warfarin, and several anticonvulsants. Strong CYP3A4 inducers (rifampin, carbamazepine) reduce exposure to both THC and CBD; strong CYP3A4 inhibitors (ketoconazole, clarithromycin) raise it.
| intro               = '''Cannabis''' (''Cannabis sativa'' L.) is an annual flowering plant of the family Cannabaceae, native to Central Asia and cultivated by humans for at least eight thousand years. It is among the oldest and most widely used psychoactive medicines in the world. Its principal psychoactive constituent, '''[[THC|delta-9-tetrahydrocannabinol]]''' (THC), was isolated and structurally characterized by Yechiel Gaoni and Raphael Mechoulam in Israel in 1964, an event that effectively founded modern cannabinoid science. The discovery of specific brain receptors for THC, the '''CB1''' receptor (cloned by Matsuda and colleagues in 1990) and the predominantly peripheral '''CB2''' receptor (Munro and colleagues in 1993), and of the body's own ligands for them (the '''endocannabinoids''', led by anandamide in 1992 from Devane and colleagues in Mechoulam's group) revealed an entire previously unrecognized signaling system, the '''endocannabinoid system''', that participates in pain, mood, appetite, immune function, sleep, reward, and the regulation of neurotransmitter release.<ref name="matsuda1990">Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. ''Nature''. 1990 Aug 9;346(6284):561-4. PMID: 2165569.</ref><ref name="munro1993">Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. ''Nature''. 1993 Sep 2;365(6441):61-5. PMID: 7689702.</ref><ref name="devane1992">Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. ''Science''. 1992 Dec 18;258(5090):1946-9. PMID: 1470919.</ref>


Pharmacopedia treats cannabis as a single plant entity with many preparations and many constituents, rather than as a single compound. The individual cannabinoids have their own pages ([[THC]], [[CBD]], [[CBN]], [[CBG]], [[THCV]]); their pharmaceutical isolates ([[Dronabinol]], [[Nabilone]], [[Nabiximols]], [[Cannabidiol]]) have their own pages; this page is the botanical source.
The earliest physical traces are of the fiber: cord-marked pottery from Taiwan has been dated to around the sixth millennium BC, and the use of hemp for cloth and rope is documented across early China. The plant's medicinal use is recorded in the Chinese tradition by the first centuries of the common era, where it was gathered into the body of plant knowledge attributed to the legendary herbalist Shennong; that tradition valued cannabis as a remedy while also warning that taken to excess it could disorder the mind. In India, cannabis enters the written record in the ''Atharvaveda'', which names it among a small number of sacred plants said to release anxiety, and it became woven permanently into devotional life, associated above all with the god Shiva and consumed as the milk-and-cannabis preparation called bhang.
| botany              = Cannabis is a wind-pollinated dioecious annual (occasionally monoecious) with palmately compound leaves of 5 to 9 (sometimes more) serrated leaflets. Plants reach 1 to 5 metres at maturity. The female flowers, clustered into dense inflorescences ("colas") at branch tips, are the source of the bulk of the medicinal and psychoactive material; they bear capitate-stalked glandular trichomes whose heads contain the cannabinoid- and terpene-rich resin.


The genus has long carried a contested taxonomy. The older Linnaean treatment recognised ''Cannabis sativa'' (Linnaeus 1753); Lamarck added ''Cannabis indica'' in 1785; Janischewsky described ''Cannabis ruderalis'' in 1924. Modern taxonomists are divided between a single polymorphic species (''C. sativa'' with subspecies) and multiple species, and chemists have largely sidestepped the question in favour of chemovar classification (type I through V, by dominant cannabinoid profile). The familiar "sativa" and "indica" labels used in the dispensary market are unreliable proxies for plant chemistry and have only loose correspondence to the botanical taxa they ostensibly name.
To the north and west, the plant belonged to the Scythians, the horse peoples of the Eurasian steppe. In the fifth century BC the Greek historian Herodotus described how the Scythians would sit inside a small closed tent, throw cannabis onto heated stones, and inhale the rising smoke until they "shouted aloud" with exhilaration. For a long time this was read as travelers' embroidery, until archaeology bore it out: excavations of steppe burial mounds, and of the frozen tombs of the Altai mountains, have repeatedly turned up cannabis seeds, charred residues, and the small braziers Herodotus described.<ref name="ren2019">Ren M, Tang Z, Wu X, et al. The origins of cannabis smoking: Chemical residue evidence from the first millennium BCE in the Pamirs. ''Science Advances''. 2019 Jun 12;5(6):eaaw1391. PMID: 31206023.</ref> The plant was, for these cultures, both a funerary offering and a means of reaching an altered state.
| traditional_uses    = Cannabis is among the most anciently used psychoactive plants in the human record. Charred cannabis residues in burners at the Jirzankal cemetery (Pamir Plateau, western China) have been dated to roughly 500 BCE; Herodotus (5th century BCE) describes Scythian funerary use of cannabis vapour; Chinese medical texts (the ''Shennong Bencaojing'', compiled around 200 CE but drawing on earlier oral tradition) list cannabis (''má''麻) as a treatment for menstrual disorders, gout, rheumatism, malaria, beriberi, constipation, and absent-mindedness. The Hindu ''Atharvaveda'' (~1500 BCE) names cannabis among five sacred plants. In medieval Islamic medicine the plant appears in Avicenna's ''Canon of Medicine'' (~1025 CE) under the name ''shahdanaj''. In nineteenth-century Europe and America, cannabis tincture was a routine pharmacopoeial item, championed in the West by the Irish physician William Brooke O'Shaughnessy after his Indian residency in the 1830s; the United States Pharmacopeia listed cannabis as a treatment from 1850 until its removal in 1942.<ref name="russo2017epi">Russo EB. Cannabis and epilepsy: An ancient treatment returns to the fore. ''Epilepsy Behav''. 2017 May;70(Pt B):292-297. PMID: 27989385.</ref>
| traditional_geography = Central Asian origin spread west into Persia, the Arab world, and the Mediterranean; east into China and the Indian subcontinent (where its place in Hindu and later Sikh and Sufi devotional life is deep); south into Sub-Saharan Africa (where the Bantu term ''dagga'' and the Arabic ''hashīsh'' name the substance in distinct preparation traditions); and via the Atlantic trade and Indian indenture, into the Caribbean and the Americas. By the twentieth century cannabis was effectively a global plant. The modern recreational and medical industries trace their immediate lineage through Mexican, Caribbean, and North African preparation traditions transplanted to North America and Europe in the early 20th century.
| preparations        = Cannabis is consumed in many forms, each with markedly different pharmacokinetics. Pharmacopedia does not endorse any particular route; the following are descriptive, not prescriptive.


* '''Flower''' (dried unpollinated female inflorescences): smoked or vaporized. Onset within 5 to 10 minutes; peak effect at 30 minutes; duration 2 to 4 hours. Bioavailability of inhaled THC varies widely with technique, between roughly 10% and 35%.
Cannabis spread along the trade routes of the medieval Islamic world, where its resin, hashish, was widely used despite an uneasy and shifting relationship with religious and legal authority. The Persian physician Avicenna discussed it in his medical writing, and the drug attached itself to one of the most durable legends of the period, the story linking the word "hashish" to the sect known to Crusader chroniclers as the Assassins, a tale far more legend than history but one that fixed cannabis in the European imagination for centuries.
* '''Hash''' (resin pressed from trichome heads): more concentrated than flower; same routes as flower.
* '''Kief''' (loose, sifted trichomes): traditional intermediate between flower and hash; smoked or sprinkled.
* '''Tincture''' (alcohol or oil extract): taken sublingually or orally. Sublingual onset 15 to 45 minutes, duration 4 to 6 hours; oral onset 30 to 120 minutes, duration 6 to 10 hours.
* '''Edible''' (cannabinoid-infused food, oil, or capsule): the slow route. Oral bioavailability of THC is low (4 to 12%) and highly variable owing to first-pass metabolism; onset 30 to 180 minutes; duration 6 to 10 hours. The slow onset accounts for a substantial fraction of acute cannabis toxicity, including in adults who under-estimate effect at 60 minutes and re-dose.
* '''Vaporized concentrate''' (rosin, BHO/butane hash oil, distillate): high-THC preparations vaporized through a "dab rig" or vape cartridge. Rapid onset, intense effect, pharmacokinetics resembling inhaled flower but at much higher doses.
* '''Full-spectrum extract''' (sublingual or oral oil retaining the plant's cannabinoid + terpene profile): the formulation behind FDA-approved [[Cannabidiol|Epidiolex]] (purified CBD) and the European/UK [[Nabiximols|Sativex]] (1:1 THC:CBD oromucosal spray).
* '''Isolate''' (single purified cannabinoid, typically CBD): the basis for several FDA-approved products and over-the-counter wellness markets.
| constituents        = More than 120 cannabinoids and more than 200 terpenes have been catalogued in ''Cannabis sativa''. The plant's clinical and recreational effects emerge from the combined action of multiple constituents, an idea Ethan Russo and others have called the '''entourage effect''': the proposition that whole-plant extracts produce different effects from isolated cannabinoids at equivalent THC dose because of contributions from minor cannabinoids and terpenes.<ref name="russo2011">Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. ''Br J Pharmacol''. 2011 Aug;163(7):1344-64. PMID: 21749363.</ref> The evidence for the entourage effect in controlled trials is genuinely mixed; the framework is useful as a way of thinking about cannabis chemistry but should not be confused with established clinical doctrine.


'''Principal cannabinoids:'''
Cannabis entered modern Western medicine through a single decisive figure. In the late 1830s an Irish physician, William Brooke O'Shaughnessy, working in Calcutta, studied the Indian medical use of the plant, experimented with cannabis preparations on patients, and published accounts that introduced it to British and then American doctors.<ref name="oshaughnessy1843">O'Shaughnessy WB. On the Preparations of the Indian Hemp, or Gunjah. ''Provincial Medical Journal and Retrospect of the Medical Sciences''. 1843;5(123):363-369.</ref> Within a decade cannabis extracts were a normal part of the Western pharmacy: it was listed in the United States Pharmacopeia from 1850, and was prescribed for pain, for spasm, for sleeplessness, and for a wide range of other complaints. In 1894 the British government's Indian Hemp Drugs Commission, after an extensive inquiry, concluded that moderate use of the drug produced no significant harm, a finding strikingly at odds with the panic that would follow.


* '''[[THC|Δ9-Tetrahydrocannabinol]]''' (THC, delta-9-THC), the principal psychoactive constituent. CB1 partial agonist with high efficacy in the central nervous system. Responsible for the characteristic "high," appetite stimulation, anti-nausea effect, analgesia, and the bulk of dose-related dysphoria, anxiety, and cognitive impairment.
That panic defines the plant's twentieth century. In the United States, cannabis prohibition grew less from medicine than from social fear: the drug was associated, in press and in political rhetoric, with Mexican immigrants and Black musicians, and a campaign of lurid newspaper stories tied it to insanity and violence. The newly created Federal Bureau of Narcotics, under its first commissioner Harry Anslinger, made cannabis a central target. The Marihuana Tax Act of 1937 effectively ended the drug's legal medical use in the United States, over the formal objection of the American Medical Association; cannabis was dropped from the United States Pharmacopeia in 1942. Through the international drug-control treaties of the following decades and the United States Controlled Substances Act of 1970, which placed cannabis in the most restrictive category, prohibition became near-global.
* '''[[CBD|Cannabidiol]]''' (CBD), non-psychoactive at typical doses; negative allosteric modulator of CB1, weak partial agonist at CB2, agonist at 5-HT1A and TRPV1, inhibitor of fatty acid amide hydrolase (FAAH; raises endogenous anandamide), and inhibitor of multiple CYP enzymes (notably CYP2C19, CYP3A4, CYP2C9, and several UGTs). FDA-approved (as Epidiolex) for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex.<ref name="russo2017epi" />
* '''[[CBN|Cannabinol]]''' (CBN), a degradation product of THC; weakly psychoactive; reputed sedative, evidence equivocal.
* '''[[CBG|Cannabigerol]]''' (CBG), a non-psychoactive precursor cannabinoid; preclinical anti-inflammatory and antibiotic activity; clinical evidence preliminary.
* '''[[THCV]]''' (Δ9-tetrahydrocannabivarin), structurally similar to THC but with a CB1 antagonist profile at low doses and partial agonist activity at higher doses; investigational appetite suppressant and metabolic agent.
* Cannabichromene (CBC), cannabidivarin (CBDV), cannabicyclol (CBL), and many others present at low concentrations.


'''Principal terpenes''' (volatile aroma molecules whose proportions vary widely between chemovars; some traverse the blood-brain barrier and have demonstrated CNS activity in their own right):
{{PendellsCorner
| quote  = The laws against marijuana use have a great deal more to do with racism and religious bigotry than with public health.
| volume = Poeia
| page  = 194
}}


* '''Myrcene''' (musky, herbal): often dominant in cannabis; sedative in preclinical models; the largest single terpene contributor to the "indica" stereotype.
The most recent chapter is a slow reversal. Beginning with California's legalization of medical use in 1996, a steadily growing number of jurisdictions have re-permitted cannabis for medical and then for recreational use; Uruguay in 2013 and Canada in 2018 legalized it nationally, and many United States states have done so even as it remains federally prohibited, a dissonance still unresolved. In 2018 the first cannabis-derived medicine, a purified cannabidiol preparation, was approved by the United States Food and Drug Administration for rare forms of epilepsy. After a century of prohibition, cannabis is once again, unevenly and contentiously, a medicine.
* '''Limonene''' (citrus): anxiolytic-like effects in preclinical studies.
| botany          = Cannabis is an annual flowering plant of the family Cannabaceae, the small plant family it shares with the hop. It is typically dioecious, meaning individual plants are either male or female, though plants that carry both sexes occur. The resin that carries the plant's psychoactive compounds is produced most densely by the unfertilized flowering tops of female plants, in tiny stalked glands called trichomes. Whether the genus contains a single variable species or several, most often named ''Cannabis sativa'', ''Cannabis indica'', and ''Cannabis ruderalis'', has been debated by botanists for two centuries and is still not settled; the names ''sativa'' and ''indica'' as used in commerce do not reliably correspond to the botanical distinctions.
* '''α-Pinene''' (pine): acetylcholinesterase inhibition in vitro; may partially offset THC-induced short-term memory impairment.
* '''Linalool''' (floral, lavender): anxiolytic-like and analgesic in preclinical models.
* '''β-Caryophyllene''' (peppery): unusually for a terpene, a direct CB2 agonist; investigated in inflammation and pain.
| indications        = <problem ref="chronic-pain" author="MDElliottMD"/>
<problem ref="chemotherapy-nausea" author="MDElliottMD"/>
<problem ref="appetite-stimulation-hiv-cancer" author="MDElliottMD"/>
<problem ref="dravet-syndrome" author="MDElliottMD"/>
<problem ref="lennox-gastaut-syndrome" author="MDElliottMD"/>
<problem ref="multiple-sclerosis-spasticity" author="MDElliottMD"/>
<problem ref="ptsd-symptoms" author="MDElliottMD"/>
<problem ref="insomnia" author="MDElliottMD"/>
| dosing              = '''Inhaled (flower / vapor):''' titrate by single inhalation; wait 10 to 15 minutes between inhalations to allow for full effect before re-dosing. The "start low, go slow" principle is more important for tolerance-naive users than the absolute dose.


'''Oral (edible):''' THC 2.5 to 5 mg starting dose for cannabis-naive adults; wait at least 2 hours before considering a second dose. The slow oral onset is the single most common cause of acute over-intoxication.
{{PendellsCorner
| quote  = Cannabis may be mankind's first cultivated plant, but it has never lost its wildness.
| volume = Poeia
| page  = 179
}}
| constituents    = Cannabis produces a large family of characteristic compounds known as cannabinoids, of which two are most significant. [[THC|Tetrahydrocannabinol]] (THC) is the principal psychoactive constituent, responsible for most of the intoxicating effect; it was first isolated and characterized in 1964 by the Israeli chemists Yechiel Gaoni and Raphael Mechoulam.<ref name="gaoni1964">Gaoni Y, Mechoulam R. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. ''Journal of the American Chemical Society''. 1964;86(8):1646-1647. DOI: 10.1021/ja01062a046.</ref> [[Cannabidiol|Cannabidiol]] (CBD) is a second major cannabinoid that is not intoxicating in the way THC is, and which has attracted significant medical interest in its own right. The plant also yields smaller quantities of other cannabinoids, among them [[CBN|cannabinol]] (CBN), a breakdown product of THC, and [[CBG|cannabigerol]] (CBG). The relative proportions of these compounds vary widely between plants.


'''Sublingual (tincture):''' THC 2.5 mg starting; CBD 25 mg starting (for non-seizure indications); titrate over days to weeks.
{{PendellsCorner
| quote  = Plant poisons are herbal music, the music of the grasses.
| volume = Poeia
| page  = 181
}}
| preparations    = Cannabis has been prepared and consumed in many forms across its history. The dried flowering tops and leaves are the most familiar form. Hashish, long associated with the cultures of the Middle East, North Africa, and South Asia, is the separated and compressed resin of the plant. In the Indian tradition, bhang is a drink combining ground cannabis with milk and spices. The plant's seeds yield a nutritious oil, and its stalk yields the fiber used for millennia to make rope and cloth, a use entirely separate from any psychoactive purpose.
| pharmacodynamics = The cannabinoids act on the body through what is now called the endocannabinoid system, a signalling system of receptors and naturally occurring molecules that was discovered, in the late twentieth century, precisely through the effort to understand how cannabis works. THC is understood to act chiefly as a partial agonist at the receptor known as CB1, which is abundant in the brain, and this action is understood to underlie most of its psychoactive effects. The body produces its own molecules that act on these same receptors, the first of which, anandamide, was identified in 1992.<ref name="devane1992">Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. ''Science''. 1992 Dec 18;258(5090):1946-1949. PMID: 1470919.</ref> That these receptors and molecules exist is well established; the full account of what the endocannabinoid system does, and of how cannabis produces its more complex effects, remains an active area of research.
| effects          = The effects of cannabis are dose-dependent, vary considerably between individuals and between preparations, and depend heavily on the setting and the expectations of the user. Commonly reported effects include euphoria, relaxation, an altered sense of time, increased appetite, a heightening of the senses, and a tendency for thought to move associatively. The experience can also include anxiety, and at higher doses acute distress or transient perceptual disturbance.


'''Epidiolex (purified CBD) for refractory epilepsy:''' 5 mg/kg/day divided BID, increased after one week to 10 mg/kg/day; further escalation per response and tolerability, to a typical maximum of 20 mg/kg/day. Monitor liver function.
{{PendellsCorner
| quote  = Now in the primeval silence of some unexplored tropical forest I spread my feathery leaves, a giant fern, and swayed and nodded in the spice-gales over a river whose waves at once sent up clouds of music and perfume. My soul changed to a vegetable essence, thrilled with a strange and unimagined ecstasy.
| volume  = Poeia
| page    = 191
| source  = Fitzhugh Ludlow, The Hasheesh Eater
}}
| interactions    = <pharmaInteractions/>
| counseling      = Cannabis has a notably low risk of fatal overdose: there is no well-established lethal dose, and death from cannabis toxicity alone is, on the available evidence, exceedingly rare. This does not mean its use is without risk. Regular heavy use can lead to cannabis use disorder, a recognized form of dependence with a withdrawal syndrome. The most serious and most debated concern is psychiatric: cannabis use, particularly heavy use, particularly of high-potency preparations, and particularly beginning in adolescence, is associated in a substantial body of research with an increased risk of psychotic illness, and is recognized as especially inadvisable for people with a personal or family history of psychosis.<ref name="marconi2016">Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. ''Schizophrenia Bulletin''. 2016 Sep;42(5):1262-1269. PMID: 26884547.</ref> Smoking cannabis exposes the lungs to combustion products and can contribute to respiratory symptoms. Cannabis can acutely impair coordination, judgment, and reaction time, which matters for driving. As with all medicines, figures for these risks are population estimates that vary between studies, and individual response varies considerably between people.


'''Nabiximols (Sativex):''' 1 spray (2.7 mg THC + 2.5 mg CBD per spray) up to 12 sprays/day, titrated.
{{PendellsCorner
 
| quote  = '''in its natural form''', one of the safest therapeutically active substances known to man
These figures are for orientation; cannabis dosing varies enormously by preparation, individual response, and tolerance state.
| volume  = Poeia
| effects              = '''Common acute effects''' (THC-dominant preparations): euphoria, relaxation, altered time perception, intensification of sensory experience, increased appetite, dry mouth, conjunctival injection, tachycardia (typically 20 to 50 bpm above baseline), short-term memory impairment, motor coordination deficits, slowed reaction time.
| page    = 196
 
| source = Francis Young, US DEA Administrative Law Judge, 1988
'''Common adverse effects''': anxiety (especially in inexperienced users and at high doses), paranoia, dysphoria, dizziness, nausea (paradoxically; cannabis hyperemesis syndrome with chronic high-dose use), psychomotor slowing.
}}
 
| anecdotes       = {{PendellsCorner
'''Serious effects''': acute psychosis (especially with high-THC preparations and in predisposed individuals), severe anxiety or panic, cardiovascular events in those with underlying disease, accidental over-intoxication (particularly with edibles), interaction-mediated effects (see Interactions).<ref name="volkow2014">Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. ''N Engl J Med''. 2014 Jun 5;370(23):2219-27. PMID: 24897085.</ref>
| quote  = The Cannabis ally has a way of pretending that she's not doing anything. ... Experienced ganja smokers adjust and lead quite ordinary-looking and often successful lives. ... Some of them get high every day. But just as tobacco and heroin habitues need their ally to feel normal, so the hemp smoker can confuse his intoxication for the ground state a mistake the doctor of our lineage ought never make.
 
'''Long-term effects'''(chronic regular use): tolerance to most acute effects, cannabis use disorder in roughly 9% of ever-users (rising to ~17% of those starting in adolescence), cannabis hyperemesis syndrome in some chronic heavy users, possible increased risk of incident psychotic illness in those predisposed (the magnitude and direction of this association remain genuinely contested), cognitive and motivational effects in heavy long-term use whose persistence after cessation is debated. Pulmonary effects from smoked cannabis (chronic bronchitis) are documented but pulmonary-function decline parallel to tobacco smoking has not been clearly demonstrated.
| pharmacokinetics    = '''Absorption''' varies dramatically by route. Inhaled THC reaches peak plasma concentration within 5 to 10 minutes; oral THC peaks at 60 to 180 minutes with low and variable bioavailability (4 to 12%) owing to first-pass hepatic and intestinal metabolism. Sublingual and oromucosal preparations sit between the two.
 
'''Distribution''' is wide and tissue-favoured: THC is highly lipophilic and accumulates in adipose tissue, from which it redistributes slowly over days to weeks. Volume of distribution is approximately 10 L/kg, dominated by tissue rather than plasma compartments.<ref name="grotenhermen2003">Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. ''Clin Pharmacokinet''. 2003;42(4):327-60. PMID: 12648025.</ref>
 
'''Metabolism''' is hepatic. THC is hydroxylated to '''11-hydroxy-THC''' (a comparably active metabolite, perhaps more potent at CB1 than parent THC), then further oxidized to the inactive '''11-nor-9-carboxy-THC''' (the metabolite tested for in workplace drug screening). The principal enzymes are [[Enzyme:CYP2C9|CYP2C9]] (~80% of THC clearance) and [[Enzyme:CYP3A4|CYP3A4]] (most of the remainder). CBD is metabolized predominantly by [[Enzyme:CYP2C19|CYP2C19]] and [[Enzyme:CYP3A4|CYP3A4]], and is itself a clinically meaningful inhibitor of CYP2C19, CYP2C9, CYP3A4, and several UGTs.
 
'''Elimination''' is biphasic. The distribution-phase half-life is short (hours); the terminal-phase half-life, reflecting redistribution from adipose, is long (1 to 3 days after a single dose, lengthening to 5 to 13 days in chronic users). Approximately two-thirds of the inactive metabolites are excreted in faeces, the remainder in urine. The long terminal half-life is the basis for the multi-week detection window in urine drug screening of chronic users.
| pharmacodynamics    = Cannabis acts on the body through the '''endocannabinoid system''', a signalling network discovered as a direct consequence of the search for THC's target. The two G-protein coupled cannabinoid receptors '''CB1''' and '''CB2''' are widely expressed.
 
CB1 is the principal mediator of cannabis's central effects. It is one of the most abundant GPCRs in the brain, with highest density in cortex, basal ganglia, cerebellum, and hippocampus, and largely absent from the brainstem respiratory centres, a feature that explains the near-impossibility of fatal respiratory depression from cannabis even at very high doses (in stark contrast to opioids). CB1 activation predominantly inhibits neurotransmitter release: it sits presynaptically and acts as a retrograde signal, dampening release of glutamate, GABA, and other neurotransmitters. The endogenous ligands anandamide (N-arachidonoylethanolamide) and 2-arachidonoylglycerol (2-AG) are produced on demand from membrane phospholipids rather than stored in vesicles, a defining feature of endocannabinoid signalling.
 
CB2 is expressed predominantly on immune cells (and at lower density in some neural populations); CB2 signalling modulates inflammation and pain transmission.
 
THC is a partial agonist at both CB1 and CB2. CBD, by contrast, is a '''negative allosteric modulator''' of CB1 (reducing its activation by both THC and endogenous ligands) and a weak partial agonist at CB2; it also acts at 5-HT1A (anxiolytic implications), TRPV1 (analgesic implications), GPR55, PPARγ, and several others, and inhibits FAAH, raising endogenous anandamide. This explains why CBD blunts some but not all of THC's effects when the two are co-administered, and why CBD's clinical effects are not predicted by the CB1 model alone.
 
The endocannabinoid system regulates appetite, mood, pain perception, immune function, sleep, reward, learning and memory, and the developmental wiring of neuronal circuits. This breadth is also why cannabis interacts with so many areas of medicine.
| interactions        = <pharmaInteractions/>
| prohibition_history = Cannabis was a routinely available pharmaceutical in the United States until the 1937 '''Marihuana Tax Act''', driven politically by Harry Anslinger's Federal Bureau of Narcotics and a campaign that drew heavily on racialized panic about Mexican and African-American users rather than on any new pharmacological data. The American Medical Association opposed the Act at the time. The United States Pharmacopeia removed cannabis in 1942. International control followed under the 1961 Single Convention on Narcotic Drugs. In the United States the 1970 Controlled Substances Act placed cannabis in Schedule I, where it remains federally as of 2026, although the federal posture has been functionally accommodating to state-level reform since the 2010s.
 
State-level medical-cannabis programs began with California's Proposition 215 in 1996; recreational adult-use legalization began with Colorado and Washington in 2012. By the mid-2020s most US states have at least medical-cannabis programs; many have adult-use markets. International reform has paralleled this trajectory at varying paces: Uruguay (2013), Canada (2018), several European jurisdictions in the 2020s. The federal-state regulatory dissonance in the United States remains the principal obstacle to standardized research-grade cannabis study, although the 2018 Farm Bill (legalizing hemp-derived CBD at the federal level) and the FDA's 2018 approval of Epidiolex created the first federally-authorized cannabis medicines.<ref name="russo2017epi" />
| pregnancy_details    = THC crosses the placenta and concentrates in breast milk. Prenatal cannabis exposure is associated with low birth weight and modest neurodevelopmental effects in observational cohorts, though disentangling cannabis-specific effects from tobacco co-use, alcohol co-use, and socioeconomic confounding has been methodologically difficult. Most obstetric authorities recommend abstinence in pregnancy and lactation pending higher-quality data. CBD safety in pregnancy is poorly characterized.
| monitoring          = For Epidiolex (purified CBD) and other high-dose cannabidiol regimens, monitor hepatic transaminases (ALT, AST) at baseline, 1, 3, and 6 months, and then as clinically indicated; transaminase elevations occur in roughly 10% of patients and are dose-related. For chronic cannabis users with cardiovascular comorbidity, monitor for tachycardia and orthostasis. For chronic heavy users developing cyclic vomiting, consider cannabis hyperemesis syndrome.
| counseling          = Cannabis affects different people very differently, and the same person differently at different times and in different settings. Starting low and going slow, especially with edibles whose slow onset invites under-estimation and re-dosing, prevents the great majority of acute over-intoxications. People with personal or strong family histories of psychotic illness should be aware of the modest but real association between high-THC use and psychosis. Combining cannabis with alcohol or other sedating substances markedly increases impairment. Driving under the influence of cannabis is dangerous and illegal in most jurisdictions regardless of cannabis's local legal status.
 
If you take other medicines, especially those metabolized by CYP2C9, CYP2C19, or CYP3A4, or any anticonvulsant, blood thinner, or immunosuppressant, tell your prescriber about cannabis use. The interactions are real but generally manageable when known.
 
If you find yourself relying on cannabis to feel ordinary, that's worth examining; tolerance and dependence are real, even when the substance itself rarely causes severe physical harm.
| anecdotes           = {{PendellsCorner
| quote  = The Cannabis ally has a way of pretending that she's not doing anything. ... Experienced ganja smokers adjust and lead quite ordinary-looking and often successful lives. ... Some of them get high every day. But just as tobacco and heroin habitues need their ally to feel normal, so the hemp smoker can confuse his intoxication for the ground state &mdash; a mistake the doctor of our lineage ought never make.
| volume = Poeia
| volume = Poeia
| page  = 200
| page  = 200
}}
}}
| seealso             = [[THC]], [[CBD]], [[CBN]], [[CBG]], [[THCV]], [[Dronabinol]], [[Nabilone]], [[Nabiximols]], [[Cannabidiol]], [[:Category:Cannabinoids|Cannabinoids]], [[Enzyme:CYP2C9]], [[Enzyme:CYP3A4]]
| seealso         = [[THC]], [[CBD]], [[CBN]], [[CBG]], [[THCV]], [[Dronabinol]], [[Nabilone]], [[Nabiximols]], [[Cannabidiol]], [[:Category:Cannabinoids|Cannabinoids]]
| references           = <references/>
| references       = <references/>
}}
}}